stockrow
Friday 6 November 2026
Export NCNA’s income statement to Excel — free account
NuCana PLC Sponsored ADR
NCNA Healthcare Biotechnology
- EPS
- +99.9%
- Free cash flow
- +55.7%
Quarter to June 2026, against a year earlier
0.94
0.01
+1.08%
Follow NCNA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 2 | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | (11) | (33) | (24) | (33) | (46) | (66) | (48) | (40) | (29) | (40) | (14) | +15.4% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (8) | (30) | (18) | (27) | (39) | (56) | (40) | (34) | (24) | (39) | (13) | +18.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (1,694.12) | (5,750.00) | (2,850.00) | (4,200.00) | (5,200.00) | (5,350.00) | (3,750.00) | (3,300.00) | (1,636.07) | (17.23) | (120.10) | (39.9%) | ||||||
| Cash flow | (2,615.73) | (2,158.25) | (2,549.47) | (4,681.91) | (3,652.47) | (3,150.04) | (2,754.24) | (3,132.14) | (1,646.49) | (4.38) | (1.61) | (50.8%) | ||||||
| Capex | (156.42) | (271.40) | (338.70) | (247.71) | (275.72) | (484.19) | (61.61) | 250.91 | (25.23) | (0.11) | (0.07) | (55.2%) | ||||||
| Free cash flow | (2,772.15) | (2,429.65) | (2,888.17) | (4,929.62) | (3,928.20) | (3,634.23) | (2,815.85) | (2,881.23) | (1,671.72) | (4.50) | (1.68) | (51.0%) | ||||||
| Book value | 7,126.90 | 23,153.79 | 17,017.45 | 12,478.65 | 16,764.64 | 8,666.84 | 4,579.14 | 1,763.61 | 512.77 | 14.28 | 6.50 | (49.9%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | +98.0% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (13) | (11) | (16) | (30) | (28) | (33) | (29) | (33) | (24) | (10) | (7) | (2.7%) | |||||
| Capex | (1) | (1) | (2) | (2) | (2) | (5) | (1) | 3 | 0 | 0 | 0 | (11.3%) | ||||||
| Free cash flow | (13) | (13) | (18) | (32) | (30) | (38) | (29) | (30) | (25) | (10) | (7) | (3.0%) | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 32 | 117 | 104 | 75 | 120 | 82 | 44 | 15 | 5 | 29 | 24 | (1.2%) | |||||
| Net debt | (27) | (112) | (103) | (66) | (112) | (83) | (52) | (21) | (9) | (32) | (26) | +1.9% | ||||||
| Shareholders’ equity | 34 | 120 | 109 | 81 | 127 | 90 | 48 | 19 | 8 | 32 | 27 | (0.7%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (10.00) | (36.94) | (15.36) | (26.53) | (34.54) | (45.51) | (44.36) | (64.46) | (90.80) | (132.97) | (45.24) | (123.0) pt | |||||
| ROIC | (107.68) | (223.69) | (297.89) | (138.85) | (173.43) | (569.78) | 0.00 | 0.00 | 0.00 | (16,444.30) | (1,130.23) | (16,336.6) pt | ||||||
| ROE | (10.41) | (38.49) | (16.11) | (28.78) | (37.79) | (51.24) | (57.50) | (103.93) | (185.84) | (195.06) | (68.70) | (184.6) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 16 | 20 | 24 | 31 | 29 | 33 | 31 | 28 | 22 | 12 | — | (3.1%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
NuCana PLC Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | Compare |
| AZTR Azitra, Inc. | $4.4M | 1.3× | — (loss-making) | −93.38% (below 0%: shrinking) | n/m | −19.55% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| XBIO Xenetic Biosciences, Inc. | $4.4M | — (loss-making) | — (loss-making) | +11.99% (above 0%: growing) | n/m | −128.11% (below 0%: shrinking) | 100.00% | (147.09%) | Compare |
| OSRH OSR Health, Inc. | $4.1M | — (loss-making) | — | −72.20% (below 0%: shrinking) | n/m | −398.76% (below 0%: shrinking) | 27.43% | (960.69%) | Compare |
| NCNA NuCana PLC Sponsored ADR | $4.0M | — (loss-making) | — | — | n/m | +55.66% (above 0%: growing) | 0.00% | 0.00% | |
| PMCB Nuvilex Inc. | $4.0M | — (loss-making) | — | −103.94% (below 0%: shrinking) | n/m | +60.84% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CELZ Creative Medical Technology Holdings, Inc. | $4.0M | — (loss-making) | — (loss-making) | 0.00% | n/m | −27.05% (below 0%: shrinking) | 66.67% | 0.00% | Compare |
| DRMA Dermata Therapeutics, Inc. | $3.8M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CVKD Cadrenal Therapeutics, Inc. | $3.6M | — (loss-making) | — | — | n/m | +26.24% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $4.1M | — | — | −36.10% | — | −4.78% | 47.05% | 0.00% |